Has John Grieveson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $24,382 in general payments to John Grieveson, MD across 1,290 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Grieveson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Grieveson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Grieveson, MD

Family Medicine · Lowell, MANPI 1326018813

Payments from drug & device makers

$24,382in general payments, 2019–2025

Across 1,290 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$3K
AbbVie$3K
Amgen$2K
Pfizer$1K
Lilly USA, LLC$1K
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
plus $12K from 53 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	165	$3,269
AbbVie(2 entities)	141	$2,665
Amgen	104	$1,975
Pfizer	80	$1,466
Lilly USA, LLC	76	$1,450
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	85	$1,417
Novo Nordisk	73	$1,343
GSK	65	$1,131
Bayer	49	$1,123
Teva Pharmaceuticals USA, Inc.	60	$629
Merck	32	$610
Sumitomo Pharma America, Inc.	26	$573
Sanofi-aventis U.S. LLC	22	$451
Boehringer Ingelheim	21	$447
Sunovion Pharmaceuticals Inc.	16	$380
Mylan Specialty L.p.	20	$372
Nestle Healthcare Nutrition Inc.	20	$359
Redhill Biopharma Inc.	18	$344
Novartis	15	$323
Otsuka America Pharmaceutical, Inc.	15	$291
Ironwood Pharmaceuticals, Inc	14	$290
Amarin Pharma, Inc.	14	$263
Astellas Pharma US Inc	13	$254
Eisai Inc.	15	$217
Alkermes, Inc.	6	$205
Shield Therapeutics Inc	13	$202
Ardelyx, Inc.	9	$198
Exact Sciences	8	$176
Abbott	9	$158
Johnson & Johnson(2 entities)	7	$142
Phathom Pharmaceuticals, Inc.	7	$137
Kowa Pharmaceuticals America, Inc.	8	$131
Viiv Healthcare Company	1	$125
Daiichi Sankyo Inc.	7	$124
Dexcom, Inc.	4	$113
Biohaven Pharmaceutical Holding Company Ltd.	4	$99
Takeda Pharmaceuticals U.S.A., Inc.	5	$95
Ultragenyx Pharmaceutical Inc.	4	$88
Endo Pharmaceuticals Inc.	4	$79
Avion Pharmaceuticals	5	$70
E.r. Squibb & Sons, L.L.C.	3	$64
Vanda Pharmaceuticals Inc.	3	$61
Genentech USA, Inc.	3	$57
Paratek Pharmaceuticals, Inc.	2	$46
Biohaven Pharmaceuticals, Inc.	2	$43
Lucid Diagnostics Inc.	2	$37
Alfasigma USA, Inc.	2	$37
Echosens North America, Inc.	2	$31
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$29
Sandoz	1	$22
Phadia US Inc.	1	$22
Viatris Specialty LLC	1	$22
Vertex	1	$20
Gilead	1	$19
Esperion Therapeutics, Inc.	1	$18
Antares Pharma, Inc.	1	$18
Amphastar Pharmaceuticals, Inc.	1	$18
Idorsia Pharmaceuticals US Inc	1	$17
Kaleo, Inc.	1	$16

How this compares

$24,382 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$123,409

Medicare patients

196

Services billed

1,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Lowell

Robert BeckWestford$2.1M
Katherine Gergen BarnettBoston$226K
Peter O'DwyerBoston$163K
Kelly LannuttiWeymouth$122K
Larry CulpepperBoston$109K
Jennifer WeylerWorcester$105K
Megan McCoyFramingham$75K
Kristina GraceyWorcester$73K
Suzanne MitchellBoston$69K
James SalemisRoslindale$24K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →